All GLG News Analyses Filed Under: Endocrinology
Analysis of: DXA Reimbursement Reductions: Implications for Quality Osteoporosis Care, Marjorie Luckey, MD and Roberta Biegel (Washington, DC: National Osteoporosis Foundation, Winter 2005) | osteoporosisblogger.com
Author: GLG Member Program Contributor
Analysis of: Aradigm Announces Data Showing No Occurrence of Primary Lung Cancer in Patients Treated with AERx Insulin Diabetes Management System (iDMS) | pharmalive.com
Author: GLG Member Program Contributor
Government Cuts in Funding for DXA in Physicians' Offices May Lead to Difficulties for Rural Patients
Analysis of: DXA Reimbursement Reductions: Implications for Quality Osteoporosis Care, Marjorie Luckey, MD and Roberta Biegel (Washington, DC: National Osteoporosis Foundation, Winter 2005) | osteoporosisblogger.com
Author: William Fink, President Managed Care Pharmacy Consultants, Inc
Analysis of: Study Shows Once-yearly Aclasta Better Than Risedronate at Increasing Bone Mass in Patients with Osteoporosis Caused by Glucocorticoids | pharmalive.com
Author: GLG Member Program Contributor
Analysis of: Study Shows Once-yearly Aclasta Better Than Risedronate at Increasing Bone Mass in Patients with Osteoporosis Caused by Glucocorticoids | pharmalive.com
Author: GLG Member Program Contributor
Analysis of: Study Shows Once-yearly Aclasta Better Than Risedronate at Increasing Bone Mass in Patients with Osteoporosis Caused by Glucocorticoids | pharmalive.com
Author: GLG Member Program Contributor
Posted April 16, 2008AtheroGenics' AGI-1067 Shows Some Promise, But There Are Still Questions
Analysis of: AtheroGenics Announces Encouraging Interim Results From Phase 3 Clinical Trial of AGI-1067 in Type 2 Diabetes | www.fiercebiotech.com
Author: Eric Gruff, Principal E4 Consulting
Analysis of: Amgen Drug Helps Bones | online.wsj.com
Author: GLG Member Program Contributor
Analysis of: New Data Showed Actos (pioglitazone HCl) Prevented Progression of Atherosclerotic Plaque Volume in Patients With Type 2 Diabetes | pharmalive.com
Author: GLG Member Program Contributor
Analysis of: Taranabant looks promising | www.taranabant-health.com
Author: GLG Member Program Contributor
More GLG News in
Healthcare
New Abbott Study of Investigational Vicodin CR(TM) Meets Primary Efficacy Endpoints in Phase III Trial
www.prnewswire.com
Abbott Scientists Present A New Approach for Treating Attention-Deficit Hyperactivity Disorder
biz.yahoo.com
FDA Approves Strattera® for Maintenance of ADHD in Children and Adolescents
newsroom.lilly.com
Speculators knock OPEC off oil-price perch
www.atimes.com
LASIK Worries? Some May See Better with Alternatives
www.washingtonpost.com
NNRs: A Novel direction?
May 12, 2008
LONG TERM ADIICTION CENTER MEDICAL DIRECTOR COMMENTS ON USE OF NARCOTIC ANALGESICS.
May 12, 2008
Analysis of Wal-Mart's Generics Plan
May 8, 2008
May be jumping into phase II too soon
May 7, 2008
Is LASIK the issue or is choosing the right refractive surgery for the right patient the real issue?
May 7, 2008

